Sino Biopharma’s M&A move pays off with big licensing deal
The Chinese drugmaker stands to gain more than $7 billion from a partnership with Germany’s Boehringer if its therapies can deliver clinical and commercial results Key Takeaways: Most of the…
PrimeGenX looks to a Hong Kong IPO as a cure for its cash woes
The developer of anti-inflammatory treatments will need to persuade investors to look past its balance sheet problems and its narrow pipeline of products Key Takeaways: The company is making a…
Drug spin-off trend gains traction with IPO by Hengrui offshoot
A company set up to develop Hengrui Pharma’s weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the “NewCo” business model Key Takeaways: Hengrui’s…